
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, which reflects improved financial performance relative to prior estimates. The company's clinical candidate, OKI-219, exhibited promising tolerability, with no reports of hyperglycemia and only Grade 1 treatment-related adverse events, indicating a favorable safety profile. These factors contribute to a positive outlook for OnKure, suggesting potential advancements in their clinical pipeline and overall financial resilience.
Bears say
OnKure Therapeutics is projected to incur a significant net loss of $4.56 per share for the full year of 2025, indicating financial deterioration compared to previous estimates. Key risks contributing to this negative outlook include potential negative clinical results associated with its lead asset, OKI-219, as well as delays in advancing pipeline candidates and obtaining regulatory approvals. Additionally, the company faces competitive pressures from other selective PI3Kα inhibitors and the risk of long-term dilution impacting shareholder value.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares